Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Часто задаваемые вопросы
В каком секторе работает Galmed Pharmaceuticals Ltd (GLMD)?
Galmed Pharmaceuticals Ltd относится к сектору Здравоохранение.
Какова текущая цена акций Galmed Pharmaceuticals Ltd (GLMD)?
По последним данным, цена акций Galmed Pharmaceuticals Ltd составляет 4,63 $, предыдущее закрытие — 3,83 $. За последнюю торговую сессию акции Galmed Pharmaceuticals Ltd выросли на 0,81 $, что соответствует росту на 21,05%.
Выплачивает ли Galmed Pharmaceuticals Ltd (GLMD) дивиденды?
Нет, Galmed Pharmaceuticals Ltd не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Galmed Pharmaceuticals Ltd (GLMD)?
У компании Galmed Pharmaceuticals Ltd бета 0.666, что указывает на более низкую волатильность по сравнению с рынком в целом.
